



Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia

Chin Kook Rhee^{*,f}, Kyung Hoon Min^{#,f}, Nam Yeol Yim[†], Ji Eun Lee⁺, Na Rae Lee⁺, Man Pyo Chung[§] and Kyeongman Jeon[§]

ABSTRACT: The clinical characteristics and optimal duration of corticosteroid treatment for acute eosinophilic pneumonia (AEP) have not been fully evaluated. This was a retrospective study of prospectively collected data from 137 patients with AEP, treated with standardised protocol, to clarify the clinical characteristics and compare the efficacies of 2 weeks versus 4 weeks of corticosteroid treatment for AEP.

The majority of the patients altered their smoking habits within a median (interquartile range) of 17 (13–26) days prior to development of AEP. 80 (58%) patients presented with acute respiratory failure. A total of 127 (92%) patients were treated with corticosteroids: 4 weeks, n=42; 2 weeks, n=85. Major symptoms were resolved in 3 days and the severity of respiratory failure was inversely correlated with clinical outcomes. After adjusting for differences in baseline characteristics between the groups, the differences in adjusted mean (95% confidence interval) for resolution of dyspnoea and disappearance of all symptoms were 0.57 (-0.71–1.86) and -0.04 (-1.91–1.83) days, respectively. The difference in adjusted proportion of resolution of radiological abnormalities was 6.92% (-8.19–22.02).

In conclusion, the duration of corticosteroid treatment could be shortened to 2 weeks, even in patients with respiratory failure.

KEYWORDS: Acute disease, pulmonary eosinophilia, respiratory insufficiency, smoking, treatment outcome

Acute eosinophilic pneumonia (AEP) is an acute febrile illness with severe hypoxaemia, diffuse pulmonary infiltrates, an increase in bronchoalveolar lavage (BAL) eosinophils and no evidence of infection or previous atopic illness [1]. Less than 100 cases of AEP have been reported to date [2], with the largest series including only 33 patients [3]. Therefore, clinical characteristics, especially the course of resolution of symptoms and resolution of radiographic abnormalities, have not yet been fully evaluated.

AEP is also characterised by rapid response to corticosteroids with few relapses and improvement of radiographic abnormalities without fibrosis [1, 4]. However, the proposed corticosteroid regimen varies greatly with a wide range of recommended dosages. The optimal duration of corticosteroid treatment is also uncertain, and there have been no controlled trials to guide clinicians in their use of corticosteroids. In addition, there are several reports of patients improving spontaneously without corticosteroid treatment [3, 5, 6].

A retrospective analysis of clinical data from 137 cases of AEP was performed to clarify clinical

characteristics, including resolution of associated symptoms and resolution of radiological abnormalities, after corticosteroid treatment. In addition, the efficacy and safety of a short course (2 weeks) of corticosteroid treatment was compared to a long course (4 weeks) of treatment.

MATERIALS AND METHODS

The medical records of all consecutive patients who were diagnosed with AEP at the Armed Forces Capital Hospital, an 874-bed referral military hospital in Gyeonggi province, South Korea, between May 2007 and October 2010 were retrospectively reviewed. The study was approved by the institutional review board of the Armed Forces Capital Hospital to review and publish information from the patients' records. The requirement for informed consent was waived because of the retrospective nature of the study.

Study subjects

All consecutive patients who were suspected to have AEP with a febrile illness with respiratory symptoms and diffuse pulmonary infiltrates were prospectively registered for the study period. Definite diagnosis of AEP was based on a

AFFILIATIONS

*Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea,

#Division of Respiratory Medicine, Dept of Internal Medicine, Korea University Guro Hospital, Korea University Medical School,

§Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,

†Dept of Diagnostic Radiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, and

+Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, The Armed Forces Capital Hospital, Seongnam, Republic of Korea.

^fBoth authors contributed equally.

CORRESPONDENCE

K. Jeon
Division of Pulmonary and Critical Care Medicine
Dept of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
81 Inwon-ro
Gangnam-gu Seoul
135-710
Republic of Korea
E-mail: kjeon@skku.edu

Received:

Dec 17 2011

Accepted after revision:

May 07 2012

First published online:

May 17 2012

European Respiratory Journal
Print ISSN 0903-1936
Online ISSN 1399-3003

modification of criteria proposed by PHILIT *et al.* [5] as followed: 1) acute onset of febrile respiratory manifestations <1 month in duration; 2) bilateral diffuse infiltrates on chest radiograph; 3) >25% eosinophils on BAL or eosinophilic pneumonia on lung biopsy; and 4) absence of known causes of pulmonary eosinophilia including drugs, toxins and infections. Unlike PHILIT *et al.* [5], patients with or without hypoxaemia were included to identify all possible cases of AEP [7].

Baseline data, treatment protocol and measurements during follow-up

The following data were recorded at the time of presentation: general characteristics of the patients including demographic data, detailed smoking history including the duration of smoking, symptoms and signs, and laboratory measurements including arterial oxygen tension (P_{a,O_2})/inspiratory oxygen fraction (F_{I,O_2}) ratio. In all instances, patients were interviewed about exposures that may have resulted in pulmonary eosinophilia and drug histories were reviewed. In addition, patients with a history of eating raw or undercooked freshwater crab or crayfish underwent evaluation for potential parasite infection and serologic tests. Chest radiograph and high-resolution computed tomography (HRCT) of the lungs were performed for all patients. Bronchoscopy with BAL was carried out at the time of presentation based on the constellation of clinical and radiological findings. BAL was performed using the standard techniques as previously described [8]. Once wedged, 30 mL of normal saline at room temperature was instilled through the bronchoscope and was then retrieved using a negative suction pressure adjusted to avoid visible airway collapse (<100 mmHg). The procedure was then repeated until a total of at least 120 mL was instilled. The percentages of eosinophils in BAL fluid were determined on cytocentrifuged slides using standard criteria.

After confirmative diagnosis of AEP was made, corticosteroid treatment was initiated according to a standardised protocol. The attending physician chose a regimen based on the presence of respiratory failure defined as a $P_{a,O_2}/F_{I,O_2}$ ratio ≤ 300 and/or tachypnea (respiration rate >30 breaths \cdot min $^{-1}$). When the patient had respiratory failure, 60 mg of methylprednisolone was administered intravenously every 6 h for 3 days and then changed to 30 mg oral prednisolone twice a day (fig. 1). When the patient had no respiratory failure, 30 mg oral prednisolone was administered twice a day (fig. 1). When the oxygenation was not severe ($P_{a,O_2}/F_{I,O_2}$ ratio >350) and dyspnoea symptoms were mild, corticosteroids were not administered. From May 2007 to May 2008, 4-week corticosteroid treatment was administered. However, in June 2008, the treatment duration was reduced to 2 weeks because of potential side-effects of long-term corticosteroid use. From June 2008 to March 2009, both 4-week and 2-week treatments of corticosteroids were administered. From April 2009 to October 2010, only 2-week corticosteroid treatments were administered. These regimens of corticosteroid treatment are described in figure 1.

During treatment, clinical symptoms and signs were evaluated daily by an attending physician. Moreover, laboratory tests and chest radiographs were performed weekly. Follow-up HRCT was performed 14 days after the initiation of corticosteroid treatment. The time to resolution of individual vital signs and clinical status abnormalities was defined as the first day that the vital sign or clinical variable was stable [9].

Evaluation of radiological findings

Chest radiographs were reviewed for the presence of pulmonary infiltrates and pleural fluids. HRCT images were also reviewed for the presence of each of the following signs: ground-glass opacity, air-space consolidation, nodular opacity, interlobular septal thickening, thickening of bronchovascular bundle, and pleural effusion [10]. During follow-up, clearances of pulmonary infiltrates and pleural effusion, defined as the absence of any radiographic sign, were established. Radiological findings were retrospectively analysed by two of the authors (C.K. Rhee N.Y. Yim). Differences in observed findings were resolved by consensus.

Data analysis

Because the majority of the data did not follow a normal distribution, all results are presented as median (interquartile range (IQR)) or n (%). Categorical variables were analysed using Pearson's Chi-squared tests or Fisher's exact tests. Continuous variables were analysed using Mann-Whitney U-tests. Spearman's correlation coefficient, rho (ρ), was used to assess whether there was a relationship between $P_{a,O_2}/F_{I,O_2}$ ratio at the time of presentation and clinical outcomes, including resolution of associated symptoms and signs, and intensive care unit (ICU) stay. In order to compare the efficacies of 2 weeks *versus* 4 weeks of corticosteroid treatment, differences in baseline characteristics between the two groups were adjusted if the p-value was <0.2 [11]. Adjusted mean time to resolution of individual clinical symptoms was calculated using a general linear model. Adjusted proportion of patients with pulmonary infiltration on HRCT at day 14 was calculated by logistic regression analysis. All tests were two-sided, and a p-value <0.05 was considered statistically significant.

RESULTS

During the study period, 160 patients suspected to have AEP were entered into the registry. Out of these patients, 22 (14%) patients were excluded because eosinophils on BAL were $<25\%$, even though it was also increased (12–25%). In addition, a patient diagnosed with 2009 influenza A (H1N1)-associated AEP was excluded from the study [12]. Ultimately, 137 patients with a definite diagnosis of AEP were included in this study.

Clinical characteristics

The clinical characteristics at the time of presentation of 137 patients with AEP are shown in table 1. All patients were young males with a median (IQR) age of 20 (19–21) yrs. 135 (99%) patients were current smokers. In the month prior to developing AEP, 71 of these patients had started smoking with no previous history of smoking, 41 had restarted smoking after at least 1 yr of cessation, and 13 had increased the number of cigarettes smoked per day. Of the 125 patients who had recently changed their smoking habits, the time from initiation of smoking or increased number of cigarettes to presentation of symptoms was 17 (13–26) days. 16 (12%) patients had a pre-existing allergic disease. However, other causes related to pulmonary eosinophilia were not found. Most common symptoms were cough (95%), dyspnoea (92%) and fever (88%). The level of fever was higher in patients with chills (38.2 (37.4–39.0) $^{\circ}$ C) compared to patients without chills (37.2 (37.2–38.2) $^{\circ}$ C; $p<0.001$). Inspiratory crackles were present on chest auscultation in 92 (67%) patients. A total of 108 (79%) patients were admitted to the ICU and 29

Days	4-week treatment course		2-week treatment course			
	Respiratory failure	No respiratory failure	Respiratory failure	No respiratory failure		
D1	Intravenous methylprednisolone 60 mg every 6 h	Oral prednisolone 30 mg twice a day	Intravenous methylprednisolone 60 mg every 6 h	Oral prednisolone 30 mg twice a day		
D2						
D3						
D4	Oral prednisolone 30 mg twice a day		Oral prednisolone 30 mg twice a day			
D5						
D6						
D7						
D8					Oral prednisolone 20 mg twice a day	Oral prednisolone 20 mg twice a day
D9						
D10						
D11	Oral prednisolone 25 mg twice a day	Oral prednisolone 25 mg twice a day	Oral prednisolone 20 mg once a day	Oral prednisolone 20 mg once a day		
D12						
D13						
D14	Oral prednisolone 20 mg twice a day	Oral prednisolone 20 mg twice a day	Oral prednisolone 10 mg once a day	Oral prednisolone 10 mg once a day		
D15						
D16						
D17	Oral prednisolone 15 mg twice a day	Oral prednisolone 15 mg twice a day				
D18						
D19						
D20	Oral prednisolone 15 mg once a day	Oral prednisolone 15 mg once a day				
D21						
D22						
D23	Oral prednisolone 10 mg once a day	Oral prednisolone 10 mg once a day				
D24						
D25						
D26	Oral prednisolone 5 mg once a day	Oral prednisolone 5 mg once a day				
D27						
D28						

FIGURE 1. Standardised treatment protocol for acute eosinophilic pneumonia at the Armed Forces Capital Hospital, Seongnam, Republic of Korea.

(21%) patients to a general ward. 80 (58%) patients presented with respiratory failure with decreased oxygenation ($P_{a,O_2}/F_{I,O_2}$ ratio <300); however, mechanical ventilation was needed for only three (2%) patients, two of whom were intubated.

Laboratory findings

Laboratory findings at the time of presentation are shown in figure 1. Leukocytosis of peripheral blood ($>10,000$ cells· μL^{-1}) was seen in 97 (71%) patients. Eosinophilia (>500 cells· μL^{-1}) was detected in the peripheral blood of 44 (32%) patients whose median level of eosinophil was 719 (593–997) cells· μL^{-1} . The median $P_{a,O_2}/F_{I,O_2}$ ratio at initial presentation was 284.3 (232.7–334.1). Bronchoscopy with BAL was performed in all patients on the day of presentation, and the median percentage of eosinophils on BAL fluid was 40 (35–53)%. The percentage of lymphocyte fluid was also elevated 19 (12–28)%. There were no bacterial, fungal or parasitic isolates from BAL fluid.

Radiological findings

HRCT findings at the time of presentation are shown in table 2. The most common finding was ground-glass opacity in 133 (97%) patients, followed by pleural effusion in 121 (88%) patients. Interlobular septal thickening was present in 93 (68%) patients. Centrilobular nodules were present in 71 (52%) patients and all cases had poorly defined centrilobular nodules. In addition, air-space consolidation was found in 51 (37%) patients and thickening of bronchovascular bundles was present in 24 (18%) patients. However, air-space consolidation was more frequently observed in patients with respiratory failure compared to patients without respiratory failure (47% versus 19%; $p=0.002$).

Treatment response and follow-up

A total of 127 (92%) patients were treated with corticosteroids at the time of AEP diagnosis (table 3). Among them, 90 patients

TABLE 1 Clinical characteristics and laboratory findings at the time of presentation in 137 patients with acute eosinophilic pneumonia (AEP)

Characteristics	
Age yrs	20 (19–21)
Male	137 (100)
History of allergic disease	16 (12)
Rhinitis	10
Dermatitis	3
Bronchial asthma	3
Smoking history	
Current smoker	135 (99)
Started smoking within 1 month of developing AEP	71
Resumed smoking within 1 month of developing AEP after cessation	41
Increased number of cigarettes smoked per day within 1 month of developing AEP	13
No change in smoking habits	10
Former smoker	1 (1)
Never-smoked	1 (1)
Time from initiation of smoking to presentation days[#]	17 (13–26)
Symptoms	
Cough	130 (95)
Dyspnoea	127 (93)
Fever	120 (88)
Chill	76 (56)
Headache	40 (29)
Myalgia	31 (23)
Chest pain	22 (16)
Inspiratory crackle on chest auscultation	92 (67)
Laboratory findings	
White blood cell count cells·μL^{-1}	12070 (9435–16835)
Leukocytosis >10000 cells· μL^{-1}	97 (71)
Peripheral eosinophil count cells·μL^{-1}	360 (220–583)
Eosinophilia >500 cells· μL^{-1}	44 (32)
C-reactive protein mg·dL⁻¹	16.6 (9.1–36.6)
$P_{a,O_2}/F_{i,O_2}$ ratio	284.3 (232.7–334.1)
Eosinophils on BAL %	40 (35–53)
Lymphocytes on BAL %	19 (12–28)
Neutrophil on BAL %	5 (2–11)
Admitted to ICU	108 (79)
Need for mechanical ventilation	3 (2)
Invasive	2
Noninvasive	1

Data are presented as n (%), median (interquartile range) or n. P_{a,O_2} : arterial oxygen tension; F_{i,O_2} : inspiratory oxygen fraction; BAL: bronchoalveolar lavage; ICU: intensive care unit. [#]: time from initiation of smoking or increased number of cigarettes to presentation of symptoms in 125 patients who had changed their smoking habits.

were administered intravenous methylprednisolone for 3 days followed by oral prednisolone and 37 patients received oral prednisolone only. 42 patients received a 4-week course of treatment and 85 patients received a 2-week course of treatment. The remaining 10 (7%) patients did not receive any corticosteroid treatment based on their symptoms and degree of oxygenation,

TABLE 2 High-resolution computed tomography (HRCT) findings at the time of presentation in 137 patients with acute eosinophilic pneumonia

HRCT findings	Patients
Ground-glass opacity	133 (97)
Interlobular septal thickening	93 (68)
Centrilobular nodules	71 (52)
Air-space consolidation	51 (37)
Thickening of bronchovascular bundles	24 (18)
Pleural effusion	121 (88)
Bilateral	107
Unilateral	14

Data are presented as n (%) or n.

but improved spontaneously. All symptoms improved after a median of 7 (4–10) days; defervescence occurred within 48 h in all patients and dyspnoea was improved within 3 (2–5) days. Median counts of peripheral eosinophil decreased to 129 (48–472) cells· mL^{-1} 7 days after corticosteroid treatment. However, the eosinophil counts increased again 14 days after the treatment (284 (92–743) cells· mL^{-1}) compared to those at 7 days after the treatment. This trend was also observed in frequencies of eosinophilia (>500 cells· μL^{-1}) after treatment (24% at 7 days and 36% at 14 days) (table 3). At 7 days, both pulmonary infiltrates and pleural effusion were still visible on chest radiographs in 19 (15%) patients. HRCT taken at 14 days showed pulmonary infiltrates present in 13 (10%) patients and pleural effusion present in three (2%) patients. Adverse effects were noted in 25 (20%) patients. One patient developed herpes zoster, 12 (9%) patients developed epigastric pain and 14 (11%) patients developed dyspepsia.

Severity of respiratory failure as measured by $P_{a,O_2}/F_{i,O_2}$ ratios correlated inversely with improvement of dyspnoea ($\rho = -0.329$, $p < 0.001$), discontinuation of oxygen ($\rho = -0.463$, $p < 0.001$) and ICU stay ($\rho = -0.287$, $p = 0.003$) (table 4).

All patients were discharged with complete resolution of symptoms and radiologic abnormalities. A total of 42 (31%) patients were followed up for 74 (60–153) days after discharge from the hospital. Of these 42 patients, 23 (55%) had started smoking again, but an AEP relapse occurred in only one patient who resumed smoking 44 days after stopping cigarette smoking.

Comparison of efficacy of 2 weeks versus 4 weeks of corticosteroid treatment

Comparisons of baseline characteristics of patients who received 2 weeks and 4 weeks of corticosteroid treatment are summarised in table 5. Patients who received corticosteroid treatment for 4 weeks were more likely to have a fever and inspiratory crackle on chest auscultation when compared with those who received corticosteroid treatment for 2 weeks. CRP levels and neutrophil counts in BAL fluid were significantly higher and $P_{a,O_2}/F_{i,O_2}$ ratio was significantly lower in the 4-week group. After adjusting for fever, myalgia, crackle on chest auscultation, C-reactive protein, peripheral eosinophilia and neutrophil count in BAL

TABLE 3 Treatment responses in 127 patients with acute eosinophilic pneumonia who received corticosteroid treatment

Corticosteroid treatment	127 (93)
Intravenous methylprednisolone followed by oral prednisolone	90
Oral prednisolone only	37
No treatment	10 (7)
Clinical outcomes	
Time to defervescence days	0 (0–1)
Time to improved dyspnoea days	3 (2–5)
Time to discontinuation of oxygen supplement days	2 (0–4)
Time to disappearance of all symptoms days	7 (4–10)
Duration of ICU stay days	2 (2–3)
Mortality	0 (0)
Laboratory outcomes	
Peripheral eosinophil count at 7 days cells· μL^{-1}	129 (48–472)
Eosinophilia >500 cells· μL^{-1} at 7 days	31 (24)
Peripheral eosinophil count at 14 days cells· μL^{-1}	284 (92–743)
Eosinophilia >500 cells· μL^{-1} at 14 days	46 (36)
C-reactive protein at 7 days mg·dL ⁻¹	0.28 (0.13–0.50)
C-reactive protein at 14 days mg·dL ⁻¹	0.13 (0.02–0.50)
Radiological outcomes	
Pulmonary infiltrates visible on chest radiograph at 7 days	19 (15)
Pleural effusion visible on chest radiograph at 7 days	19 (15)
Pulmonary infiltrates visible on HRCT at 14 days	13 (10)
Pleural effusion visible on HRCT at 14 days	3 (2)
Adverse effect of corticosteroid	25 (20)
Herpes zoster	1 (1)
Epigastric pain	12 (9)
Dyspepsia	14 (11)

Data are presented as n (%), n or median (interquartile range). ICU: intensive care unit; HRCT: high-resolution computed tomography.

fluid, the mean and proportion of patients were calculated in order to compare the efficacy of corticosteroid treatment between the 2- and 4-week groups (table 6). Differences in adjusted mean (95% confidence interval) for times to defervescence, resolution of dyspnoea and disappearance of all symptoms were 0.11 (-0.26–0.49) days, 0.57 (-0.71–1.86) days and -0.04 (-1.91–1.83) days, respectively. The difference in adjusted proportion for patients whose pulmonary infiltration was visible on HRCT at 14 days was 6.92 (-8.19–22.02)%. In addition, the frequency of adverse effects was similar between the 2- and 4-week group (18% versus 24%, $p=0.411$).

DISCUSSION

AEP is thought to be a rare disease and there is a limited number of case series, all with relatively small sample sizes, that have been reported in the medical literature [1, 3, 5, 6, 10, 13–15]. That said, studies with larger samples afford the best picture of the clinical characteristics of this disease. Although the present study data came from a single centre referral military hospital, 137 cases of AEP were identified. The main reason why very high number of patients could be collected in a single centre over a relatively short period is due to the unique characteristics of the medical system in the Korean army. According to the military law of the Korean army, all soldiers should be treated in

TABLE 4 Correlations between arterial oxygen tension/inspiratory oxygen fraction ratio and clinical outcomes

Clinical outcomes	Correlation coefficient (ρ)	p-value
Time to defervescence days	-0.071	0.411
Time to improved dyspnoea days	-0.329	<0.001
Time to discontinuation of oxygen supplement days	-0.463	<0.001
Time to disappearance of all symptoms days	-0.146	0.090
Duration of intensive care unit stay days	-0.287	0.003

military hospitals. The Armed Forces Capital Hospital is the only tertiary referral military hospital in Korea where bronchoscopy is available. Accordingly, all patients with suspected AEP should be transferred to the Armed Forces Capital Hospital. Although this study is single centre, enrolled patients were transferred from more than 20 military hospitals. Therefore, our cohort represented all young males at risk for AEP in the Korean army. This relatively large case series confirms clinical characteristics, radiological findings and responsiveness to standardised corticosteroid treatment previously reported in smaller case series [2]. Additionally, this series indicates that a 2-week short-course of corticosteroid treatment might be acceptable for treatment of AEP with respiratory failure.

The aetiology of AEP is unknown, but several series have suggested that cigarette smoke is related to the onset of AEP [3, 5, 7]. Most of the patients (99%) in this study were current smokers, and the majority had either restarted smoking after cessation or had started smoking for the first time within 1 month prior to presentation. The median duration from initiation of smoking to presentation of symptoms was 17 days, which is consistent with previous reports [3, 9]. Additionally, within 1 month before onset of AEP, 13 patients increased the number of cigarettes they smoked daily. Therefore, the study results support the theory that recent changes in smoking habits, including restarting after cessation and increasing the number of daily cigarettes, are associated with the development of AEP [3].

Hypoxaemic respiratory failure is frequently identified at presentation and often requires mechanical ventilation in patients with AEP. In the present study, ~60% of the patients presented with acute respiratory failure with decreased oxygenation. However, mechanical ventilation was required in only three patients. In addition, some patients did not progress to severe respiratory failure and then had a spontaneous recovery without any treatment. Interestingly, 16–27% of patients improved without definite treatment in the previous studies [5, 14]. UCHIYAMA *et al.* [3] reported that the majority of patients with AEP spontaneously improved without any treatment. Therefore, the clinical course and severity of AEP appear to be even more varied than originally reported [1].

Although spontaneous improvements have even been reported in patients with severe respiratory failure [5], death from AEP with respiratory failure can occur [7, 16]. In earlier case series, therefore, treatments with a high dose of corticosteroid were

TABLE 5 Comparisons of baseline characteristics of patients who received corticosteroid treatment for 2 weeks and 4 weeks

Characteristics	2 weeks	4 weeks	p-value
Subjects n	85	42	
Age yrs	20 (20–21)	20 (20–21)	0.863
History of allergic disease	8 (10)	3 (10)	1.000
Time from initiation of smoking to presentation days[#]	17 (14–28)	16 (11–24)	0.435
Symptoms			
Cough	80 (94)	40 (95)	1.000
Dyspnoea	78 (92)	41 (98)	0.269
Fever	69 (81)	41 (98)	0.011
Chill	46 (54)	26 (62)	0.405
Headache	28 (33)	11 (26)	0.438
Myalgia	27 (32)	3 (7)	0.002
Chest pain	13 (15)	5 (12)	0.606
Inspiratory crackle on chest auscultation	53 (62)	35 (83)	0.016
Laboratory findings			
Leukocytosis >10000 cells· μL^{-1}	59 (69)	33 (79)	0.277
Peripheral eosinophilia >500 cells· μL^{-1}	32 (38)	8 (19)	0.034
C-reactive protein mg·dL ⁻¹	12.1 (5.9–31.4)	35.6 (16.3–38.4)	<0.001
$P_{a,O_2}/F_{i,O_2}$ ratio	298.7 (262.9–344.8)	239.1 (219.3–268.8)	<0.001
Eosinophils on BAL %	40 (35–53)	40 (31–50)	0.078
Lymphocytes on BAL %	19 (12–26)	23 (12–30)	0.747
Neutrophil on BAL %	5 (2–10)	6 (4–17)	0.004

Data are presented as median (interquartile range) or n (%), unless otherwise stated. P_{a,O_2} : arterial oxygen tension; F_{i,O_2} : inspiratory oxygen fraction; BAL: bronchoalveolar lavage. [#]: data were available in 131 (97%) patients who were current smokers.

initiated and rapid improvements were reported [1, 6, 15, 17, 18]. In the present study, patients with AEP were uniformly responsive to intravenous or oral corticosteroid treatment. Interestingly, the improvements of clinical outcomes were correlated with severity of respiratory failure at presentation. In addition, the majority of pulmonary infiltrates on chest

radiographs disappeared within 7 days after corticosteroid treatment, which is consistent with previous reports [7]. However, when some patients were evaluated with computed tomography scan at 14 days, pulmonary infiltrates and pleural effusion were still present. During the follow-up period, relapse occurred in only one patient who resumed smoking 1.5 months

TABLE 6 Comparison of adjusted means or proportion of clinical outcomes of patients who received corticosteroid treatment for 2 weeks and 4 weeks

Clinical outcomes	Adjusted mean [#] (95% CI)	Adjusted proportion [†] (95% CI)	Difference between adjusted mean or proportion (95% CI)
Time to defervescence days			
2 weeks	0.66 (0.48–0.84)		0.11 (-0.26–0.49)
4 weeks	0.54 (0.24–0.85)		
Time to improved dyspnoea days			
2 weeks	3.84 (3.23–4.45)		0.57 (-0.71–1.86)
4 weeks	3.27 (2.22–4.31)		
Time to disappearance of all symptoms days			
2 weeks	7.21 (6.32–8.09)		-0.04 (-1.91–1.83)
4 weeks	7.25 (5.73–8.76)		
Pulmonary infiltration at day 14 %			
2 weeks		12.98 (5.83–20.12)	6.92 (-8.19–22.02)
4 weeks		6.06 (-6.17–18.28)	

[#]: calculated by general linear model; [†]: calculated by logistic regression analysis after adjusting for differences in fever, myalgia, crackles on chest auscultation, C-reactive protein, peripheral eosinophilia and neutrophil count on bronchoalveolar lavage fluid.

after cessation of cigarette smoking. Although previous reports had suggested that no relapses occurred in patients recovered from AEP, three additional cases of relapsed AEP are reported in the recent literature [3, 19, 20]. Interestingly, cases involving AEP relapse, including the relapse reported in the present study, are associated with resumption of smoking after temporary cessation. These observations suggest that relapse of AEP can occur in patients who resume cigarette smoking. However, the remaining 23 patients who resumed cigarette smoking in this study did not have an AEP relapse.

There is no standardised regimen of corticosteroid treatment for AEP. The literature discusses proposed and implemented regimens of corticosteroids that span a wide range of doses and durations [2]. A commonly recommended regimen is 60–125 mg intravenous methylprednisolone every 6 h, changing to 40–60 mg of oral prednisone daily tapering over 2–6 weeks [21]. However, the optimal duration of corticosteroid treatment is uncertain and has not been subjected to controlled trials [4]. This is the first study that showed clinical efficacy of standardised treatment of corticosteroids for AEP. Patients in this study were treated according to the standardised corticosteroid protocol based on the severity of disease [21], but we changed the duration of the taper from 4 weeks to 2 weeks. This made it possible to compare the efficacy and safety of 2-week versus 4-week courses of treatment. Interestingly, the efficacy of a 2-week course of corticosteroid was similar to that of a 4-week course in terms of time to resolution of clinical symptoms and resolution of radiological abnormalities. In addition, the frequency of adverse effects was also similar between the groups. These might be because a similar dosage of corticosteroid is administered during the first week of treatment in both the 2-week and 4-week regimen (fig. 1). The primary difference between the regimens was the corticosteroid tapering schedule. Therefore, the results of this study suggest that high doses of corticosteroid could be tapered over periods as short as 10 days. This is supported by the results of previous studies [1, 6]. In addition, recently reported cases from Japan received only high doses of corticosteroids intravenously for 3 days without a maintenance treatment of oral prednisolone [3]. However, these observations should be further evaluated by a prospective study.

There are several limitations to this study. First, given its retrospective nature, there is always the possibility that selection bias might have influenced the significance of our findings. However, the data were collected prospectively from all consecutive patients with AEP. Patient history, especially in terms of smoking, AEP confirmation tests and corticosteroid treatment was taken according to standardised protocol. Secondly, this study was conducted at a single military hospital and all of the enrolled patients were young males, which may limit the ability to generalise our findings to other centres or populations. However, previous reports showed that AEP develops predominantly in young patients [1, 3, 5, 7]. Finally, the baseline characteristics of the patients were not balanced when comparing the efficacies between short and long courses of corticosteroid treatment. This was addressed by the adjusted multivariate analysis. However, the potential for bias due to an unmeasured confounder remains.

In conclusion, in addition to further clarifying the major clinical characteristics of AEP and the association between

recent changes in smoking habits and development of AEP, this study suggests that respiratory symptoms of AEP can vary from mild dyspnoea to life-threatening respiratory failure. This study also found that 2 weeks of corticosteroid treatment for patients with respiratory failure could be as effective as 4 weeks of treatment, although this observation needs to be further evaluated by a prospective study.

STATEMENT OF INTEREST

None declared.

ACKNOWLEDGEMENTS

The authors thank S. Woo (Samsung Biomedical Research Institute, Seoul, Republic of Korea) for comments regarding statistical analysis.

REFERENCES

- Allen JN, Pacht ER, Gadek JE, *et al.* Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. *N Engl J Med* 1989; 321: 569–574.
- Janz DR, O'Neal HR Jr., Ely EW. Acute eosinophilic pneumonia: a case report and review of the literature. *Crit Care Med* 2009; 37: 1470–1474.
- Uchiyama H, Suda T, Nakamura Y, *et al.* Alterations in smoking habits are associated with acute eosinophilic pneumonia. *Chest* 2008; 133: 1174–1180.
- Allen J. Acute eosinophilic pneumonia. *Semin Respir Crit Care Med* 2006; 27: 142–147.
- Philil F, Etienne-Mastroianni B, Parrot A, *et al.* Idiopathic acute eosinophilic pneumonia: a study of 22 patients. *Am J Respir Crit Care Med* 2002; 166: 1235–1239.
- Pope-Harman AL, Davis WB, Allen ED, *et al.* Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. *Medicine (Baltimore)* 1996; 75: 334–342.
- Shorr AF, Scoville SL, Cersovsky SB, *et al.* Acute eosinophilic pneumonia among US military personnel deployed in or near Iraq. *JAMA* 2004; 292: 2997–3005.
- Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for a standard procedure. *Semin Respir Crit Care Med* 2007; 28: 475–485.
- Halm EA, Fine MJ, Marrie TJ, *et al.* Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. *JAMA* 1998; 279: 1452–1457.
- Daimon T, Johkoh T, Sumikawa H, *et al.* Acute eosinophilic pneumonia: thin-section CT findings in 29 patients. *Eur J Radiol* 2008; 65: 462–467.
- Fisher B, Anderson S, Fisher ER, *et al.* Significance of ipsilateral breast tumour recurrence after lumpectomy. *Lancet* 1991; 338: 327–331.
- Jeon EJ, Kim KH, Min KH. Acute eosinophilic pneumonia associated with 2009 influenza A (H1N1). *Thorax* 2010; 65: 268–270.
- Hayakawa H, Sato A, Toyoshima M, *et al.* A clinical study of idiopathic eosinophilic pneumonia. *Chest* 1994; 105: 1462–1466.
- Umeki S. Reevaluation of eosinophilic pneumonia and its diagnostic criteria. *Arch Intern Med* 1992; 152: 1913–1919.
- Tazelaar HD, Linz LJ, Colby TV, *et al.* Acute eosinophilic pneumonia: histopathologic findings in nine patients. *Am J Respir Crit Care Med* 1997; 155: 296–302.
- Kawayama T, Fujiki R, Morimitsu Y, *et al.* Fatal idiopathic acute eosinophilic pneumonia with acute lung injury. *Respirology* 2002; 7: 373–375.
- Badesch DB, King TE Jr., Schwarz MI. Acute eosinophilic pneumonia: a hypersensitivity phenomenon? *Am Rev Respir Dis* 1989; 139: 249–252.

- 18 King MA, Pope-Harman AL, Allen JN, *et al.* Acute eosinophilic pneumonia: radiologic and clinical features. *Radiology* 1997; 203: 715–719.
- 19 Shiota Y, Kawai T, Matsumoto H, *et al.* Acute eosinophilic pneumonia following cigarette smoking. *Intern Med* 2000; 39: 830–833.
- 20 Shintani H, Fujimura M, Yasui M, *et al.* Acute eosinophilic pneumonia caused by cigarette smoking. *Intern Med* 2000; 39: 66–68.
- 21 Jantz MA, Sahn SA. Corticosteroids in acute respiratory failure. *Am J Respir Crit Care Med* 1999; 160: 1079–1100.